AR118982A1 - CYCLIC BRADYKININ RECEPTOR ANTAGONISTS - Google Patents
CYCLIC BRADYKININ RECEPTOR ANTAGONISTSInfo
- Publication number
- AR118982A1 AR118982A1 ARP200101443A ARP200101443A AR118982A1 AR 118982 A1 AR118982 A1 AR 118982A1 AR P200101443 A ARP200101443 A AR P200101443A AR P200101443 A ARP200101443 A AR P200101443A AR 118982 A1 AR118982 A1 AR 118982A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- halogen atom
- alkyl
- independently
- Prior art date
Links
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 2
- 101800004538 Bradykinin Proteins 0.000 abstract 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 2
- 102100035792 Kininogen-1 Human genes 0.000 abstract 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 125000004431 deuterium atom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a un compuesto de acuerdo con la formula general (1), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene uno o más compuestos de la misma; a una preparación de combinación que contiene al menos un compuesto de la misma y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento. Reivindicación 1: Un compuesto de fórmula general (1), o una de sus sales, en donde A representa un grupo seleccionado del grupo de fórmulas (2); A¹ es N o CH; A² es N o C-RA²; A³ es N o C-RA³; A⁴ es NH, O ó S; A⁵ es N-RA⁵; RA¹ representa un átomo de hidrógeno o un grupo metilo; cada uno de RA² y RA³, independientemente entre sí, representa un átomo de hidrógeno, un átomo de halógeno, OH, CN, NH₂; alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxi C₁₋₃, que puede estar sustituido con uno o más grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; alcoxialquilo C₂₋₅, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; C(O)NRA⁶RA⁷; o NRA⁶RA⁷; RA⁵, RA⁶ y RA⁷, cada uno independientemente entre sí, representa un átomo de hidrógeno o un grupo alquilo C₁₋₃, que puede estar sustituido con uno o más, grupo(s), idénticos o diferentes, seleccionados entre un átomo de halógeno, OH, =O y NH₂; R¹ representa un grupo alquilo C₁₋₃ o alcoxialquilo C₂₋₅, dicho grupo alquilo o alcoxialquilo puede estar sustituido con uno o más grupo(s), idénticos o diferentes, seleccionados entre un átomo de deuterio, un átomo de halógeno, OH, =O y NH₂; R² representa un átomo de hidrógeno o un átomo de deuterio; B representa un grupo heterocicloalquilo que contiene nitrógeno de 5 ó 6 miembros que tiene al menos un sustituyente oxo y n sustituyentes R, en donde n indica el número 0, 1, 2, 3, 4 ó 5; y cada R, en cada ocasión independientemente, representa un átomo de halógeno, OH, NRC¹RC², =O, G, OG o un grupo cicloalquilo C₃₋₅; cada uno de RC¹ y RC², independientemente entre sí, representan un átomo de hidrógeno o un grupo alquilo C₁₋₃; G representa un grupo alquilo C₁₋₆, en donde de 1 a 5 átomos de H pueden, en cada ocasión independientemente, estar sustituidos con un átomo de halógeno, =O, ORG¹ o NRG²RG³, y/o en donde un grupo CH₂, o dos grupos CH₂ no adyacentes, pueden estar sustituidos con O, C(O), OC(O), C(O)O, C(O)NH, NHC(O), NH, S, SO y/o SO₂; RG¹, RG² y RG³, cada uno independientemente entre sí, representan un átomo de hidrógeno, un grupo alquilo C₁₋₃, haloalquilo C₁₋₃, hidroxialquilo C₁₋₃, heteroalquilo C₁₋₃ o cicloalquilo C₃₋₅.The present relates to a compound according to the general formula (1), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more compounds thereof; to a combination preparation containing at least one compound thereof and at least one additional pharmaceutically active ingredient; and to the uses of said compound(s), including use as a medicine. Claim 1: A compound of general formula (1), or one of its salts, wherein A represents a group selected from the group of formulas (2); A¹ is N or CH; A² is N or C-RA²; A³ is N or C-RA³; A⁴ is NH, O or S; A⁵ is N-RA⁵; RA¹ represents a hydrogen atom or a methyl group; each of RA² and RA³, independently of each other, represents a hydrogen atom, a halogen atom, OH, CN, NH₂; C₁₋₃ alkyl, which may be substituted with one or more identical or different group(s) selected from a halogen atom, OH, =O and NH₂; C₁₋₃ alkoxy, which may be substituted with one or more group(s), identical or different, selected from a halogen atom, OH, =O and NH₂; C₂₋₅ alkoxyalkyl, which may be substituted with one or more identical or different group(s) selected from a halogen atom, OH, =O and NH₂; C(O)NRA⁶RA⁷; or NRA⁶RA⁷; RA⁵, RA⁶ and RA⁷, each independently of one another, represents a hydrogen atom or a C₁₋₃ alkyl group, which may be substituted with one or more identical or different group(s) selected from a halogen atom, OH, =O and NH₂; R¹ represents a C₁₋₃ alkyl or C₂₋₅ alkoxyalkyl group, said alkyl or alkoxyalkyl group may be substituted with one or more group(s), identical or different, selected from a deuterium atom, a halogen atom, OH, = O and NH₂; R² represents a hydrogen atom or a deuterium atom; B represents a 5- or 6-membered nitrogen-containing heterocycloalkyl group having at least one oxo substituent and n R substituents, where n indicates the number 0, 1, 2, 3, 4 or 5; and each R, each time independently, represents a halogen atom, OH, NRC¹RC², =O, G, OG or a C₃₋₅ cycloalkyl group; each of RC¹ and RC², independently of each other, represents a hydrogen atom or a C₁₋₃ alkyl group; G represents a C₁₋₆ alkyl group, where from 1 to 5 H atoms may, on each occasion independently, be substituted by a halogen atom, =O, ORG¹ or NRG²RG³, and/or where a CH₂ group, or two non-adjacent CH₂ groups may be substituted with O, C(O), OC(O), C(O)O, C(O)NH, NHC(O), NH, S, SO and/or SO₂; RG¹, RG² and RG³ each independently of one another represent a hydrogen atom, a C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ hydroxyalkyl, C₁₋₃ heteroalkyl or C₃₋₅ cycloalkyl group.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176207 | 2019-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118982A1 true AR118982A1 (en) | 2021-11-17 |
Family
ID=66668713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101443A AR118982A1 (en) | 2019-05-23 | 2020-05-21 | CYCLIC BRADYKININ RECEPTOR ANTAGONISTS |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12312330B2 (en) |
| EP (1) | EP3983402B1 (en) |
| JP (1) | JP7462683B2 (en) |
| CN (1) | CN113906018B (en) |
| AR (1) | AR118982A1 (en) |
| AU (1) | AU2020280924B2 (en) |
| CA (1) | CA3139229A1 (en) |
| ES (1) | ES2962971T3 (en) |
| MX (1) | MX2021014288A (en) |
| PL (1) | PL3983402T3 (en) |
| TW (1) | TWI827847B (en) |
| UY (1) | UY38706A (en) |
| WO (1) | WO2020234479A1 (en) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| WO1996013485A1 (en) | 1994-10-27 | 1996-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
| FR2737892B1 (en) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | NOVEL BENZENESULFONAMIDE COMPOUNDS, PREPARATION METHOD AND THERAPEUTIC USE |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (en) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl and acylaminoalkyl ethers, processes for their preparation and their use as bradykinin receptor antagonists |
| DE19610784A1 (en) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoroalkyl and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, processes for their preparation and their use |
| DE19612067A1 (en) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Use of bradykinin antagonists for the manufacture of medicaments for the treatment of chronic fibrogenetic liver diseases and acute liver diseases |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| AU6422098A (en) * | 1997-03-24 | 1998-10-20 | Kyowa Hakko Kogyo Co. Ltd. | Benzene derivatives |
| DE19712960A1 (en) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituted, fused N-heterocycles, processes for their preparation and their use as bradykinin receptor antagonists |
| CA2319730A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Bradykinin antagonists |
| HK1040245B (en) | 1998-10-21 | 2004-10-08 | 安斯泰来制药有限公司 | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (en) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | NOVEL N- (BENZENESULFONAMIDE) COMPOUNDS, METHOD OF PREPARATION AND THERAPEUTIC USE |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| US6509366B2 (en) | 2000-01-18 | 2003-01-21 | Neurogen Corporation | Substituted imidazoles as selective modulators of Bradykinin B2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| EP1914236A1 (en) * | 2002-04-10 | 2008-04-23 | Ortho-McNeil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| JP2005525398A (en) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Novel heteroarylalkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (en) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | NON-PEPTID BASIC ANTAGONISTS OF BRADICHININE AND THEIR USE PHARMACEUTICAL INFORMATION |
| ITMI20041963A1 (en) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "NON-PEPTIDIAL ANTAGONISTS OF BRADICHININ AND THEIR PHARMACEUTICAL COMPOSITIONS" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| TWI407960B (en) * | 2007-03-23 | 2013-09-11 | Jerini Ag | Small molecule bradykinin b2 receptor modulators |
| AR068509A1 (en) * | 2007-09-19 | 2009-11-18 | Jerini Ag | BRADIQUININE B1 RECEIVER ANTAGOSNIST |
| AR073304A1 (en) | 2008-09-22 | 2010-10-28 | Jerini Ag | MODULATORS OF THE BRADIQUININE B2 RECEPTOR OF SMALL MOLECULA |
| CN105228623A (en) * | 2013-03-14 | 2016-01-06 | 夏尔人类遗传性治疗公司 | The angioedematous method for the treatment of B2-bradykinin receptor mediation |
| SMT202200154T1 (en) | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Novel bradykinin b2 receptor antagonists |
| UY38707A (en) | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | NEW CYCLIC ANTAGONISTS OF BRADIQUININ B2 RECEPTOR |
-
2020
- 2020-05-21 AR ARP200101443A patent/AR118982A1/en unknown
- 2020-05-21 UY UY0001038706A patent/UY38706A/en active IP Right Grant
- 2020-05-22 TW TW109117162A patent/TWI827847B/en active
- 2020-05-25 WO PCT/EP2020/064375 patent/WO2020234479A1/en not_active Ceased
- 2020-05-25 MX MX2021014288A patent/MX2021014288A/en unknown
- 2020-05-25 CA CA3139229A patent/CA3139229A1/en active Pending
- 2020-05-25 CN CN202080038066.3A patent/CN113906018B/en active Active
- 2020-05-25 PL PL20732502.8T patent/PL3983402T3/en unknown
- 2020-05-25 EP EP20732502.8A patent/EP3983402B1/en active Active
- 2020-05-25 JP JP2021569938A patent/JP7462683B2/en active Active
- 2020-05-25 ES ES20732502T patent/ES2962971T3/en active Active
- 2020-05-25 AU AU2020280924A patent/AU2020280924B2/en active Active
- 2020-05-25 US US17/530,967 patent/US12312330B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020280924A1 (en) | 2021-11-25 |
| US20220135542A1 (en) | 2022-05-05 |
| JP7462683B2 (en) | 2024-04-05 |
| TWI827847B (en) | 2024-01-01 |
| WO2020234479A1 (en) | 2020-11-26 |
| EP3983402C0 (en) | 2023-08-16 |
| TW202110429A (en) | 2021-03-16 |
| PL3983402T4 (en) | 2024-04-02 |
| CN113906018B (en) | 2024-04-12 |
| PL3983402T3 (en) | 2024-04-02 |
| US12312330B2 (en) | 2025-05-27 |
| EP3983402A1 (en) | 2022-04-20 |
| JP2022534389A (en) | 2022-07-29 |
| UY38706A (en) | 2020-12-31 |
| CN113906018A (en) | 2022-01-07 |
| AU2020280924B2 (en) | 2023-07-27 |
| ES2962971T3 (en) | 2024-03-22 |
| EP3983402B1 (en) | 2023-08-16 |
| MX2021014288A (en) | 2022-01-06 |
| CA3139229A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113839A1 (en) | BRADIQUININ B2 RECEPTOR ANTAGONISTS | |
| AR118983A1 (en) | CYCLIC BRADYKININ RECEPTOR ANTAGONISTS | |
| CO2021003298A2 (en) | Novel sulfonamidaurea compounds | |
| UY37845A (en) | SULFONYLUREAS AND SULPHONYLTIOUREAS USEFUL AS INHIBITORS OF NLRP3 | |
| UY37795A (en) | SULFONILUREAS AND SULFONILTIOUREAS USEFUL AS INHIBITORS OF NLRP3 | |
| AR066460A2 (en) | COMPOUNDS DERIVED FROM PHENYL-PIPERAZINE, PHENYL-PIPERIDINE AND PHENYL-TETRAHIDROPIRIDINE AS INHIBITORS OF THE REABSORTION OF SEROTONIN, A PHARMACEUTICAL COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF MEDICINES | |
| BR112012018865A2 (en) | substituted naphthyridines and their use as syk kinase inhibitors | |
| AR063602A1 (en) | DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS. | |
| AR109315A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF REPLACED POLICYCLIC PIRIDONE AND PROPHARM OF THE SAME | |
| AR067475A1 (en) | NON BASIC S ANTAGONISTS OF THE RECEIVER OF THE CONCENTRATING HORMONE OF MELANINA 1 | |
| AR114828A1 (en) | PTERIDINONE COMPOUNDS AND THEIR USES | |
| AR037534A1 (en) | DERIVED FROM ADAMANTANO, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOUND AND SUCH COMPOSITION AND INTERMEDIATE COMPOUNDS | |
| AR054035A1 (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USE OF THE SAME | |
| AR065015A1 (en) | ANTRANILAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES FOR THE TREATMENT OF CANCER | |
| UY28578A1 (en) | AMIDA DERIVATIVES | |
| AR093047A1 (en) | NITROGEN HETEROCICLICAL COMPOUNDS | |
| AR094300A1 (en) | DERIVATIVES OF QUINOLONES | |
| AR123648A1 (en) | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USES | |
| AR094100A1 (en) | CARBAMATE DERIVATIVES OF CYCLHEXYL AND QUINUCLIDINYL THAT HAVE ACTIVITY AS b2 ADRENERGIC AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS | |
| AR056893A1 (en) | FUSIONED AND FUSIONED HETEROCICLIC COMPOUNDS, MINERALOCORTICOID RECEPTORS ANTAGONISTS | |
| BR112018001816A2 (en) | Adamantil Urea Analogs As Soluble Inhibitors Of Epoxide Hydrolase | |
| MX2021008252A (en) | PYRIMIDINE COMPOUND OR SALT THEREOF. | |
| AR122703A1 (en) | RIP1K INHIBITORS | |
| NO20091486L (en) | Novel imidazolone derivatives, their preparation as drugs, pharmaceutical preparations and their use as protein kinase inhibitors, in particular CDC7 | |
| AR034700A1 (en) | PIRIMIDINE DERIVATIVES, PROCESSES TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THE USE OF SUCH COMPOUNDS FOR THE DEVELOPMENT OF MEDICINES |